Overview:
Cardio-kidney-metabolic (CKM) disorders represent an increasingly prevalent and prognostically significant clinical intersection characterized by shared pathophysiological drivers that accelerate disease progression across cardiovascular, renal, and metabolic domains. Although harmonized international guidelines support the use of foundational therapies, uptake remains suboptimal. Early risk identification, evidence-based therapeutic initiation and sequencing, and coordinated multidisciplinary collaboration are critical to reducing care fragmentation and improving long-term outcomes for patients with CKM disorders.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Explain the role of guideline-directed decision-making in selecting sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy for patients with heart failure (HF) and chronic kidney disease (CKD)
- Apply strategies for monitoring in patients treated with guideline-recommended agents for HF and CKD
- Design approaches for optimizing multidisciplinary care models and patient counseling in the clinical context of cardio-kidney-metabolic (CKM) disorders
Target Audience:
This educational activity is directed towards NPs, PAs, and nurses. Other healthcare professionals involved in the care of patients with cardio-renal-metabolic diseases, including cardiologists, nephrologists, and primary care physicians are also invited to participate.